Program Description & Educational Objectives

In this activity, a urologist and two primary care physicians discuss the recognition and treatment of overactive bladder in the primary care setting.

Upon completion of this activity, participants should be better able to:

• Effectively use screening tools and clinical evaluation methods to diagnose OAB in men and women who present with lower urinary tract symptoms
• Incorporate pharmacologic and nonpharmacologic interventions into treatment plans to improve outcomes for men and women with OAB
• Educate patients with OAB and their caregivers about lifestyle modifications and behavioral therapy to improve patient outcomes

Target Audience

This activity has been designed to meet the educational needs of primary care physicians, OB/GYNs, urologists, and other clinicians involved in managing patients with overactive bladder.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of at least 70% is required on the post-test in order to receive a Statement of Credit.There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Internet
Release and Expiration Dates: December 06, 2011 - December 05, 2012
Time to Complete: 45 minutes

Faculty & Disclosure / Conflict of Interest Policy

The “Conflict of Interest Disclosure Policy” of Albert Einstein College of Medicine of Yeshiva University requires that faculty participating in any CME activity disclose to the audience any relationship(s) with a pharmaceutical, product, or device company. Any presenter who’s disclosed relationships prove to create a conflict of interest with regard to their contribution to the activity will not be permitted to present.

The Albert Einstein College of Medicine of Yeshiva University also requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

Course Director and Moderator

Eric S. Rovner, MD
Professor of Urology
Director, Section of Female Urology, Neurourology and Urodynamics
Department of Urology
Medical University of South Carolina
Charleston, South Carolina

Eric S. Rovner, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Allergan, Inc.; Astellas Pharma US, Inc.; Medtronic, Inc.; Pfizer Inc; and Tengion.
Grant/Research Support from Allergan, Inc.; Contura International A/S; Pfizer Inc; Solace Therapeutics; and Tengion.
Speakers Bureau participant with Pfizer Inc.

Interviewees

Matt Rosenberg, MD
Medical Director
Mid-Michigan Health Centers
Allegiance Health System
Jackson, Michigan

Matt Rosenberg, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Allergan, Inc.; Astellas Pharma US, Inc.; Endo Pharmaceuticals; Horizon Pharma; and Pfizer Inc.
Grant/Research Support from Astellas Pharma US, Inc.
Speakers Bureau participant with Allergan, Inc.; Astellas Pharma US, Inc.; Endo Pharmaceuticals; Ferring Pharmaceuticals; Forest Laboratories, Inc.; GlaxoSmithKline; Pfizer Inc; and Purdue Pharma L.P.

Geoffrey Leung, MD
Former Program Director
Riverside County Medical Center Family Medicine Residency Program
Moreno Valley, California

Geoffrey Leung, MD, currently has no financial interests/relationships or affiliations in relation to this activity.

CME Reviewer

Norman Z. Kahan, MD
Assistant Professor
Department of Urology
Albert Einstein College of Medicine of Yeshiva University
Bronx, New York

Norman Z. Kahan, MD, currently has no financial interests/relationships or affiliations in relation to this activity.

Content Director

Regina Janesko, MS
PVI, PeerView Institute for Medical Education

Regina Janesko, MS, currently has no financial interests/relationships or affiliations in relation to this activity.

The staff of Albert Einstein College of Medicine of Yeshiva University, Montefiore Medical Center have no disclosures to report with any commercial interests with the following exception: Steven Jay Feld, or a member of his household owns securities in Bioheart, Inc., Chelsea Therapeutics, Inc. and Pharmacopeia, Inc.

Sponsorship, Credit & Support

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Albert Einstein College of Medicine of Yeshiva University, Montefiore Medical Center and PVI, PeerView Institute for Medical Education. Albert Einstein College of Medicine of Yeshiva University is accredited by the ACCME to provide continuing medical education for physicians.

The Albert Einstein College of Medicine of Yeshiva University designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This CME activity is jointly sponsored by Albert Einstein College of Medicine of Yeshiva University, Montefiore Medical Center and PVI, PeerView Institute for Medical Education.

This activity is supported through an independent educational grant from

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.

The opinions expressed herein are those of the authors and do not necessarily represent the views of Albert Einstein College of Medicine of Yeshiva University, Montefiore Medical Center, Astellas Pharma Global Development, Inc. or PVI, PeerView Institute for Medical Education. Please review complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.